News
BIOVF
41.32
NaN%
--
Berenberg Bank Keeps Their Buy Rating on Swedish Orphan Biovitrum AB (0MTD)
TipRanks · 4d ago
Weekly Buzz: MGNX Resumes LINNET; GSK Wins China Nod; FDA Okays Waters; NBIX Snaps Up SLNO
NASDAQ · 04/10 14:00
Health Canada Approves Swedish Orphan Biovitrum's EMPAVELI In C3G And Primary IC-MPGN Kidney Disease
NASDAQ · 04/10 07:13
Sobi Calls 2026 AGM With In-Person and Postal Voting Options
TipRanks · 03/27 09:32
Swedish Orphan Biovitrum price target raised to SEK 470 from SEK 395 at Barclays
TipRanks · 02/24 17:10
Swedish Orphan Biovitrum price target raised to SEK 500 from SEK 470 at Berenberg
TipRanks · 02/23 18:00
Swedish Orphan Biovitrum downgraded to Hold from Buy at Danske Bank
TipRanks · 02/19 09:40
Sobi Sets Ambitious 2030 Target to Double Revenue on Wave of New Rare-Disease Launches
TipRanks · 02/18 09:18
Swedish Orphan upgraded to Outperform from Underperform at BNP Paribas
TipRanks · 02/10 10:00
Berenberg Bank Sticks to Its Buy Rating for Swedish Orphan Biovitrum AB (0MTD)
TipRanks · 02/09 08:36
Swedish Orphan Biovitrum AB reports Q4 results
Seeking Alpha · 02/05 11:39
Sobi Posts Strong 2025 Growth and Expands Rare Disease Portfolio With Strategic Deals and Launches
TipRanks · 02/05 08:05
Berenberg Bank Remains a Buy on Swedish Orphan Biovitrum AB (0MTD)
TipRanks · 01/23 07:47
Apellis upgraded at BofA on launch trajectory for kidney disease therapy
Seeking Alpha · 01/21 17:15
Sobi, Apellis win EU nod for Aspaveli against rare kidney diseases
Seeking Alpha · 01/16 12:39
SOBI: 2025 Revenue, Adj. EBITA Margin Higher Than Prior Guidance
NASDAQ · 01/15 12:33
Sobi Lifts 2025 Revenue and Profitability Above Previous Outlook
TipRanks · 01/15 12:03
Sobi Reports Positive Phase 2a EMBRACE Study Results For Gamifant In IFN?-Driven Sepsis
NASDAQ · 01/08 03:30
Sobi Advances Gamifant After Positive Phase 2a Data in Interferon-Gamma–Driven Sepsis
TipRanks · 01/07 17:33
Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO
NASDAQ · 12/20/2025 05:44
More
Webull provides a variety of real-time BIOVF stock news. You can receive the latest news about Swedish Orphan Biovitrum Ab through multiple platforms. This information may help you make smarter investment decisions.
About BIOVF
Swedish Orphan Biovitrum AB (publ) is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others.